Patient P-03379

Synthetic patientONX-7 · Day 115 · 75+ · F · baseline S12Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Deteriorating

Nutritional resilience

Unstable

Discontinuation risk

55%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S12
Day 10 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 102 GI-04 recommended — GI Support Protocol GI-04
Day 103 Patient accepted — Started GI-04 in the companion
Day 111 GI symptom burden −10% vs expected — GI Support Protocol GI-04
Day 117 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 10.

Primary contributors, last 14 days

Toxicity+14
Treatment adherence-8
GI instability+7
Inflammatory activity+7
Nutritional resilience-6

What helped?

GI Support Protocol GI-04Day 102
Result: symptom burden −10%

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

70%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 42
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 42/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 54
Autonomic recovery ↓25
- WearableResting HR 80 bpm

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.4 · butyrate capacity 42/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 40 ms
Sleep: 6.8 h
Steps: 7,187
Resting HR: 79 bpm

Daily log: GI score 59, nutritional resilience 42, adherence 84.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03204	30%	S16	AD-05	improved	48
P-03351	28%	S07	AD-05	no change	51
P-03105	27%	S12	AD-05	no change	60
P-03111	25%	S07	AD-05	no change	48
P-03482	25%	S05	AD-05	no change	67
P-03034	24%	S14	AD-05	no change	30
P-03187	24%	S12	AD-05	no change	80
P-03369	24%	S18	AD-05	no change	37
P-03424	24%	S12	AD-05	improved	41
P-03158	23%	S17	AD-05	no change	37
P-03380	23%	S16	AD-05	improved	34
P-03277	25%	S14	BR-03	improved	41